Search Within

Gregory J Riely

Formats
  1. Journal Article (295)
  2. Meeting Abstract (265)
  3. Book Section (16)
  4. Guidelines (15)
  5. Conference Paper (4)
  6. Review (4)
  7. Editorial (3)
  8. Book Whole (1)
  9. Correspondence (1)
  10. Research Letter (1)
Groups
  1. Department of Medicine (605)
  2. Solid Tumor Oncology Division (605)
  3. Thoracic Oncology (605)
  4. Department of Pathology and Laboratory Medicine (262)
  5. GSK Faculty (248)
  6. Human Oncology and Pathogenesis Program (223)

More Groups

People
  1. Mark Kris (222)
  2. Marc Ladanyi (188)
  3. Helena Yu (108)
  4. Maria Arcila (85)
  5. Vincent Miller (79)
  6. Charles Rudin (76)

More People

Years
  1. 2025 (9)
  2. 2024 (25)
  3. 2023 (45)
  4. 2022 (39)
  5. 2021 (41)
  6. 2020 (29)

More Years

Publications
  1. Journal of Clinical Oncology (157)
  2. Journal of Thoracic Oncology (113)
  3. Clinical Cancer Research (46)
  4. Annals of Oncology (32)
  5. Journal of the National Comprehensive Cancer Network (26)
  6. Cancer Research (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (175)
  2. Elsevier Inc. (137)
  3. American Association for Cancer Research (77)
  4. Oxford University Press (39)
  5. Harborside Press (26)
  6. Elsevier Science, Inc. (23)

More Publishers

Results (605)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 dose escalation study of a new ALK inhibitor, CH5424802/RO5424802, in ALK+ non-small cell lung cancer (NSCLC) patients who have failed crizotinib (AF-002JG/NP28761, NCT01588028)
    Meeting Abstract

    Gadgeel, S.; Ou, S. H.; Chiappori, A. A.; Riely, G.; Lee, R. M.; Garcia, L.; Sato, J.; Yokoyama, S.; Tanaka, T.; Gandhi, L.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Ret fusion-positive advanced lung cancers: Response to first-line chemotherapy and survival in comparison to ROS1 and ALK fusion-positive and EGFR- and KRAS-mutant lung cancers
    Meeting Abstract

    Drilon, A.; Wang, L.; Joubert, P.; Snyder, A.; Cho, E. J.; Riely, G.; Kris, M.; Ladanyi, M.; Rizvi, N.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Clinical, structural and biochemical characterization of EGFR exon 20 insertion mutations in lung cancer
    Meeting Abstract

    Costa, D. B.; Yasuda, H.; Park, E.; Yun, C. H.; Huberman, M. S.; Oxnard, G. R.; Sequist, L. V.; Riely, G.; Soo, R.; Eck, M. J.; more...
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases in profile 1005 and profile 1007
    Meeting Abstract

    Costa, D. B.; Shaw, A. T.; Ou, S. H. I.; Solomon, B. J.; Riely, G. J.; Ahn, M. J.; Zhou, C. C.; Shreeve, S. M.; Wiltshire, R.; Selaru, P.; more...
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Targeted cancer genome sequencing in thymic epithelial tumors
    Meeting Abstract

    Moreira, A.; McMillan, R.; Won, H.; Huang, J.; Riely, G.; Ladanyi, M.; Berger, M.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Anaplastic lymphoma kinase (ALK) positive central nervous system (CNS) metastases from non small cell lung cancer (NSCLC)
    Meeting Abstract

    Singer, S.; Riely, G. J.; Kris, M. G.; Grommes, C.
    Neuro-Oncology (2013)

    Fulltext@MSK | Save
  • Crizotinib vs. pemetrexed or docetaxel in advanced ALK+ non-small cell lung cancer: Subgroup analysis in PROFILE 1007
    Meeting Abstract

    Yamamoto, N.; Nokihara, H.; Han, J. Y.; Hida, T.; Riely, G. J.; Baldini, E.; Salvatore, S.; Horn, L.; Polli, A.; Satouchi, M.
    Annals of Oncology (2013)

    Fulltext@MSK | Save
  • Crizotinib treatment in patients (pts) with advanced ROS1-rearranged non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Ou, S. H. I.; Kim, D. W.; Camidge, R.; Riely, G. J.; Salgia, R.; Shapiro, G.; Clark, J. W.; Tye, L.; Iafrate, A. J.; Shaw, A.
    Annals of Oncology (2013)

    Fulltext@MSK | Save
  • Clinical experience with crizotinib in patients (pts) with advanced ALK plus non-small cell lung cancer (NSCLC) and brain metastases
    Meeting Abstract

    Crino, L.; Ahn, M. J.; Ou, S. H. I.; Solomon, B. J.; Costa, D. B.; Shreeve, S. M.; Wiltshire, R.; Selaru, P.; Zhou, C.; Riely, G. J.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer
    Journal Article

    Yasuda, H.; Park, E.; Yun, C. H.; Sng, N. J.; Lucena-Araujo, A. R.; Yeo, W. L.; Huberman, M. S.; Cohen, D. W.; Nakayama, S.; Ishioka, K.; more...
    Science Translational Medicine (2013)

    Fulltext@MSK | Save